Bernanke Spurs Stocks
Health Care: Drugs
Apricus Biosciences Inc. (APRI: NASDAQ)
$3.40 -0.01 | -0.32%
05/22/13 - 12:28 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| APRI | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 29.85 | 38.06 | -50.64 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 105.20 | 1.83 | 0.41 |
| Net Income | 0.00 | 0.00 | |
| EPS | -0.79 | 0.00 |
Earnings for APRI:
| EBITDA | -24.00 |
| REVENUE | 8.42M |
Average Earnings Estimates
| Qtr (03/13) | Qtr (06/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.12 | $-0.13 | $-0.58 | $-0.40 |
| Number of Analysts | 1 | 1 | 2 | 1 |
| High Estimate | $-0.12 | $-0.13 | $-0.55 | $-0.40 |
| Low Estimate | $-0.12 | $-0.13 | $-0.60 | $-0.40 |
| Prior Year | $-0.20 | $n.a. | $-0.58 | $-0.58 |
| Growth Rate (Year over Year) | 40.00% | n.a.% | 0.86% | 30.43% |
Portfolios with APRI
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
Latest APRI Headlines from TheStreet
- Apricus Biosciences Provides First Quarter 2013 Corporate Update 05.10.13 | 08:05 am
- Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call 05.07.13 | 02:05 pm
- Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting 05.07.13 | 11:05 am
- Apricus Biosciences To Present At 2013 BIO International Convention 04.18.13 | 07:04 am
- Apricus Biosciences Announces Sale Of Non-Core Assets 04.01.13 | 04:04 pm
- Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012 03.18.13 | 11:03 am
- Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer 03.18.13 | 11:03 am
- Apricus Biosciences Announces 2012 Year End Financial Results Conference Call 03.14.13 | 09:03 am
- Apricus Biosciences Announces Ceasing Of Financing Of French Subsidiaries 03.14.13 | 08:03 am
- Apricus Biosciences To Present At The 25th Annual ROTH Conference 03.13.13 | 04:03 pm
Press Releases for APRI
- Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating! - PR Newswire 03.14.12 | 09:03 am
- Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America - PR Newswire 08.08.11 | 07:08 pm
- Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros® - Business Wire 12.06.10 | 09:12 am
- Apricus Biosciences Appoints Manufacturer For Vitaros®, Its Newly Approved Drug To Treat Erectile Dysfunction In Canada - Business Wire 12.01.10 | 10:12 am
- Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published In The International Journal Of Pharmaceutics - Business Wire 11.29.10 | 10:11 am
- Apricus Biosciences Files Phase 3 Registration Protocol For PrevOnco™ For Special Protocol Assessment Consideration By The FDA - Business Wire 11.22.10 | 10:11 am
- Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement In Solubility And Absorption Of NexACT®-Based Small Molecule Drugs Selected From The Biopharmaceutics Classification System - Business Wire 11.19.10 | 10:11 am
- Apricus Biosciences’ CEO Bassam Damaj, Ph.D., Interviewed By The Financial Network CDTV.net - Business Wire 11.17.10 | 10:11 am
- Apricus Biosciences Receives Canadian Approval For Vitaros® As First Line Therapy For Erectile Dysfunction - Business Wire 11.15.10 | 12:11 pm
- Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call - Business Wire 11.10.10 | 10:11 am
Partner Headlines for APRI
- Smart Stocks Watch: Apricus Biosciences - Seeking Alpha 09.21.12 | 09:09 am
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - NASDAQ 09.14.12 | 10:09 pm
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Tesaro Initiated at OUTPERFORM and 2 Initiated Shares on the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- REVEALED: New Stock Analyst Coverage to Evaluate - Wall St. Cheat Sheet 06.14.12 | 03:06 am
- Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances - Benzinga 05.25.12 | 01:05 pm
- Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder - Benzinga 05.21.12 | 09:05 am
- Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis - Benzinga 05.11.12 | 09:05 am
- Apricus Biosciences; Vitaros Has Great Potential - Seeking Alpha 04.22.12 | 09:04 am
- Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa in the Middle East and the Gulf - Benzinga 01.10.12 | 09:01 am
